Stockscreener 앱 받기
1.02
6.42%
-0.07
시간 외 거래:
1.06
0.04
+3.92%
전일 마감가:
$1.09
열려 있는:
$1.06
하루 거래량:
330.41K
Relative Volume:
1.10
시가총액:
$76.50M
수익:
-
순이익/손실:
$-30.15M
주가수익비율:
-0.8718
EPS:
-1.17
순현금흐름:
$-31.63M
1주 성능:
-26.62%
1개월 성능:
-37.42%
6개월 성능:
-53.00%
1년 성능:
+0.99%
1일 변동 폭
$0.9606
$1.1136
1주일 범위
$0.9606
$1.39
52주 변동 폭
$0.89
$2.75
Context Therapeutics Inc Stock (CNTX) Company Profile
명칭
Context Therapeutics Inc
전화
267-225-7416
주소
2001 MARKET STREET, PHILADELPHIA
CNTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
1.02 | 76.50M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-25 | 개시 | D. Boral Capital | Buy |
| 2024-05-16 | 개시 | Piper Sandler | Overweight |
Context Therapeutics Inc 주식(CNTX)의 최신 뉴스
Top 10 Small-Cap Stocks to Watch in 2025 - Investing.com
Top 10 Small-Cap Stocks to Watch in 2025 - Investing.com
HR+ HER2-ve Breast Cancer Pipeline Therapeutics Assessment Report 2024 | DelveInsight - openPR
Context Therapeutics Inc. (NASDAQ:CNTX) Short Interest Update - MarketBeat
Short Interest in Ares Commercial Real Estate Co. (NYSE:ACRE) Declines By 8.6% - Defense World
Brooge Energy Limited (NASDAQ:BROGW) Short Interest Update - Defense World
Unpacking Q3 Earnings: Skyworks Solutions (NASDAQ:SWKS) In The Context Of Other Analog Semiconductors Stocks - Yahoo Finance
Likelihood of Approval and Phase Transition Success Rate ModelCTIM-76 in Endometrial Cancer - GlobalData
Context Therapeutics Secures Funding for Cancer Therapy Pipeline - TipRanks
Unpacking Q3 Earnings: Qorvo (NASDAQ:QRVO) In The Context Of Other Processors and Graphics Chips Stocks - Yahoo Finance
Unpacking Q3 Earnings: Norfolk Southern Corporation (NYSE:NSC) In The Context Of Other Transportation and Logistics Stocks - Yahoo Finance
Short Interest in Context Therapeutics Inc. (NASDAQ:CNTX) Declines By 13.8% - MarketBeat
Rondo Therapeutics reports CD28 x Nectin-4 bispecific antibody for bladder cancer - BioWorld Online
Unpacking Q3 Earnings: WillScot Mobile Mini (NASDAQ:WSC) In The Context Of Other Construction and Maintenance Services Stocks - Yahoo Finance
Context Therapeutics Inc. (NASDAQ:CNTX) Stock Position Lessened by Great Point Partners LLC - MarketBeat
Wells Fargo & Company Issues Pessimistic Forecast for Tractor Supply (NASDAQ:TSCO) Stock Price - Defense World
TG Therapeutics (NASDAQ:TGTX) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - Defense World
Ascendiant Capital Markets Has Lowered Expectations for LiqTech International (NASDAQ:LIQT) Stock Price - Defense World
D. Boral Capital Begins Coverage on Context Therapeutics (NASDAQ:CNTX) - Defense World
D. Boral Capital Reaffirms Buy Rating for Imunon (NASDAQ:IMNN) - Defense World
22nd Century Group (NASDAQ:XXII) Coverage Initiated at StockNews.com - Defense World
HC Wainwright Reaffirms “Neutral” Rating for RAPT Therapeutics (NASDAQ:RAPT) - Defense World
D. Boral Capital Initiates Coverage of Context Therapeutics (CNTX) with Buy Recommendation - MSN
Empyrean Therapeutics acquires TLR2 antagonist from Eos Therapies - BioWorld Online
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.04 Consensus PT from Analysts - Defense World
Context Therapeutics (NASDAQ:CNTX) Coverage Initiated at D. Boral Capital - MarketBeat
Perspective Therapeutics shares hold Outperform as RBC adjusts expectations for progress - Investing.com
Context Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Context Therapeutics: Strategic Developments and Financial Outlook - TipRanks
Aclaris Therapeutics Secures Exclusive Licensing for Novel Antibody Therapies - MyChesCo
Around the Helix: Cell and Gene Therapy Company Updates – November 20, 2024 - CGTLive™
Unpacking Q3 Earnings: AutoZone (NYSE:AZO) In The Context Of Other Auto Parts Retailer Stocks - Yahoo Finance
Tango Therapeutics director Mace Rothenberg acquires $74,000 in stock - Investing.com
Unpacking Q3 Earnings: Cadence (NASDAQ:CDNS) In The Context Of Other Design Software Stocks - Yahoo Finance
Avidity Partners Management LP Bolsters Stake in Context Therape - GuruFocus.com
Blue Owl Capital Holdings LP Acquires Shares in Context Therapeu - GuruFocus.com
Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results - Simply Wall St
GREAT POINT PARTNERS LLC Adjusts Stake in Context Therapeutics I - GuruFocus.com
Driehaus Capital Management LLC Acquires Shares in Apogee Therap - GuruFocus.com
Around the Helix: Cell and Gene Therapy Company Updates – November 13, 2024 - CGTLive™
Patient With Sickle Cell Disease Dies From Complications Related to Busulfan-Conditioning Following Treatment With Beam’s Base-Editing HSC Therapy BEAM-101 - CGTLive™
Research Analysts Set Expectations for CNTX FY2024 Earnings - MarketBeat
Circle S.p.A. Advances Digitalization in Logistics - MSN
Context Therapeutics (NASDAQ:CNTX) Announces Earnings Results - MarketBeat
Palvella Therapeutics Begins Phase 3 Trial for Microcystic Lymphatic Malformations Treatment - MyChesCo
Annovis Bio Welcomes New Senior Clinical Scientist to Lead Key Studies - MyChesCo
Redeemer Health Operating Deficit Surpasses $50 Million in Fiscal 2024 - MSN
Context Therapeutics Announces Q3 2024 Financial Results and Strategic Advances - MyChesCo
Keiretsu Forum Honors Top Innovators at Investor Capital Expo - MyChesCo
3 Promising US Penny Stocks With At Least $90M Market Cap - Simply Wall St
Century Therapeutics Expands Clinical Focus and Reports Steady Financials for Q3 2024 - MyChesCo
Context Therapeutics Inc (CNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):